Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.

Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.